Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites

Overview

Journal Nutrients

Date 2025 Jan 11

PMID 39796588

Authors

Maria Jose Garcia Mansilla

Maria Jesus Rodriguez Sojo

Andrea Roxana Lista

Ciskey Vanessa Ayala Mosqueda

Antonio Jesus Ruiz Malagon

Julio Galvez

Alba Rodriguez Nogales

Maria Jose Rodriguez Sanchez

Affiliations

Soon will be listed here.

Abstract

Irritable bowel syndrome is a common functional gastrointestinal disorder characterized by recurrent abdominal discomfort, bloating, cramping, flatulence, and changes in bowel movements. The pathophysiology of IBS involves a complex interaction between motor, sensory, microbiological, immunological, and psychological factors. Diversity, stability, and metabolic activity of the gut microbiota are frequently altered in IBS, thus leading to a situation of gut dysbiosis. Therefore, the use of probiotics and probiotic-derived metabolites may be helpful in balancing the gut microbiota and alleviating irritable bowel syndrome symptoms. This review aimed to report and consolidate recent progress in understanding the role of gut dysbiosis in the pathophysiology of IBS, as well as the current studies that have focused on the use of probiotics and their metabolites, providing a foundation for their potential beneficial effects as a complementary and alternative therapeutic strategy for this condition due to the current absence of effective and safe treatments.

References

Alnouti Y . Bile Acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009; 108(2):225-46. DOI: 10.1093/toxsci/kfn268. View

Layden B, Angueira A, Brodsky M, Durai V, Lowe Jr W . Short chain fatty acids and their receptors: new metabolic targets. Transl Res. 2012; 161(3):131-40. DOI: 10.1016/j.trsl.2012.10.007. View

Dimidi E, Christodoulides S, Fragkos K, Scott S, Whelan K . The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014; 100(4):1075-84. DOI: 10.3945/ajcn.114.089151. View

Schmulson M, Drossman D . What Is New in Rome IV. J Neurogastroenterol Motil. 2017; 23(2):151-163. PMC: 5383110. DOI: 10.5056/jnm16214. View

Mitselou A, Grammeniatis V, Varouktsi A, Papadatos S, Katsanos K, Galani V . Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease. Intest Res. 2020; 18(1):115-120. PMC: 7000645. DOI: 10.5217/ir.2019.00125. View

Pavlovic N, Stankov K, Mikov M . Probiotics--interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol. 2012; 168(7):1880-95. DOI: 10.1007/s12010-012-9904-4. View

Ruiz L, Margolles A, Sanchez B . Bile resistance mechanisms in Lactobacillus and Bifidobacterium. Front Microbiol. 2014; 4:396. PMC: 3872040. DOI: 10.3389/fmicb.2013.00396. View

Agostini S, Goubern M, Tondereau V, Salvador-Cartier C, Bezirard V, Leveque M . A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil. 2012; 24(4):376-e172. DOI: 10.1111/j.1365-2982.2011.01865.x. View

Shulman R, Jarrett M, Cain K, Broussard E, Heitkemper M . Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol. 2014; 49(11):1467-76. PMC: 4102674. DOI: 10.1007/s00535-013-0919-6. View

10.

Pace F, Pace M, Quartarone G . Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015; 61(4):273-92. View

11.

Duan R, Zhu S, Wang B, Duan L . Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review. Clin Transl Gastroenterol. 2019; 10(2):e00012. PMC: 6407812. DOI: 10.14309/ctg.0000000000000012. View

12.

Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S . Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2009; 22(5):512-9, e114-5. DOI: 10.1111/j.1365-2982.2009.01427.x. View

13.

Canakis A, Haroon M, Weber H . Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2019; 27(1):28-35. DOI: 10.1097/MED.0000000000000523. View

14.

Reich K, Fedorak R, Madsen K, Kroeker K . Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J Gastroenterol. 2014; 20(17):4934-47. PMC: 4009525. DOI: 10.3748/wjg.v20.i17.4934. View

15.

Agus A, Planchais J, Sokol H . Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018; 23(6):716-724. DOI: 10.1016/j.chom.2018.05.003. View

16.

Jeffery I, Das A, OHerlihy E, Coughlan S, Cisek K, Moore M . Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology. 2019; 158(4):1016-1028.e8. DOI: 10.1053/j.gastro.2019.11.301. View

17.

Ticho A, Malhotra P, Dudeja P, Gill R, Alrefai W . Intestinal Absorption of Bile Acids in Health and Disease. Compr Physiol. 2019; 10(1):21-56. PMC: 7171925. DOI: 10.1002/cphy.c190007. View

18.

Bravo J, Forsythe P, Chew M, Escaravage E, Savignac H, Dinan T . Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011; 108(38):16050-5. PMC: 3179073. DOI: 10.1073/pnas.1102999108. View

19.

Camilleri M . Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA. 2021; 325(9):865-877. DOI: 10.1001/jama.2020.22532. View

20.

Wouters M, Lambrechts D, Knapp M, Cleynen I, Whorwell P, Agreus L . Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut. 2013; 63(7):1103-11. DOI: 10.1136/gutjnl-2013-304570. View